CN101098859A - 嘧啶酮类化合物及其制备和用途 - Google Patents

嘧啶酮类化合物及其制备和用途 Download PDF

Info

Publication number
CN101098859A
CN101098859A CNA200580044838XA CN200580044838A CN101098859A CN 101098859 A CN101098859 A CN 101098859A CN A200580044838X A CNA200580044838X A CN A200580044838XA CN 200580044838 A CN200580044838 A CN 200580044838A CN 101098859 A CN101098859 A CN 101098859A
Authority
CN
China
Prior art keywords
radical
alkyl
compound
aryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA200580044838XA
Other languages
English (en)
Other versions
CN101098859B (zh
Inventor
姚辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Priority to CN200580044838XA priority Critical patent/CN101098859B/zh
Publication of CN101098859A publication Critical patent/CN101098859A/zh
Application granted granted Critical
Publication of CN101098859B publication Critical patent/CN101098859B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明公开了具有通式(I)的嘧啶酮类化合物，其制备方法及药物用途。该化合物是HMG-CoA还原酶抑制剂，可用于预防与治疗心脑血管疾病、老年痴呆、糖尿病、骨质疏松和癌症，并具有抗病毒和提高免疫力的功能，特别适用于治疗与血脂升高相关的疾病。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN200580044838XA 2004-12-23 2005-12-23 嘧啶酮类化合物及其制备和用途 Expired - Fee Related CN101098859B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200580044838XA CN101098859B (zh) 2004-12-23 2005-12-23 嘧啶酮类化合物及其制备和用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200410101710 2004-12-23
CN200410101710.X 2004-12-23
CN200580044838XA CN101098859B (zh) 2004-12-23 2005-12-23 嘧啶酮类化合物及其制备和用途
PCT/CN2005/002293 WO2006066512A1 (fr) 2004-12-23 2005-12-23 Dérivés de pyrimidinone, leur synthèse et leurs applications

Publications (2)

Publication Number Publication Date
CN101098859A true CN101098859A (zh) 2008-01-02
CN101098859B CN101098859B (zh) 2013-03-06

Family

ID=36601393

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580044838XA Expired - Fee Related CN101098859B (zh) 2004-12-23 2005-12-23 嘧啶酮类化合物及其制备和用途

Country Status (10)

Country Link
US (1) US7872012B2 (zh)
EP (1) EP1845092B1 (zh)
JP (1) JP4864009B2 (zh)
CN (1) CN101098859B (zh)
AT (1) ATE479662T1 (zh)
AU (1) AU2005318783B2 (zh)
CA (1) CA2591053C (zh)
DE (1) DE602005023347D1 (zh)
HK (1) HK1109393A1 (zh)
WO (1) WO2006066512A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045342A1 (de) * 1980-12-02 1982-07-01 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen Neue substituierte pyrimidin-nukleoside mit antiviraler und cytostatischer wirkung, verfahren zu deren herstellung und daraus bereitete arzneiformen
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5300477A (en) 1992-07-17 1994-04-05 Rohm And Haas Company 2-arylpyrimidines and herbicidal use thereof
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
EP1845092A1 (en) 2007-10-17
CN101098859B (zh) 2013-03-06
WO2006066512A1 (fr) 2006-06-29
DE602005023347D1 (de) 2010-10-14
US20080280930A1 (en) 2008-11-13
ATE479662T1 (de) 2010-09-15
CA2591053A1 (en) 2006-06-29
EP1845092A4 (en) 2008-09-17
AU2005318783B2 (en) 2009-04-09
EP1845092B1 (en) 2010-09-01
JP2008525326A (ja) 2008-07-17
US7872012B2 (en) 2011-01-18
HK1109393A1 (en) 2008-06-06
CA2591053C (en) 2011-03-15
JP4864009B2 (ja) 2012-01-25
AU2005318783A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
CN100400518C (zh) 2,3-二氮杂萘酮衍生物
TWI353981B (en) Preparation of rosuvastatin
US5698527A (en) Steroidal glycosides as antihyperlipidemic agents
CN101679309B (zh) 具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物
CN1821242B (zh) 制备二羟基酸HMG-CoA还原酶抑制剂的新方法
CN103347509B (zh) 用于治疗癌症的化合物和组合物
TWI481604B (zh) Novel 5-fluorouracil derivatives
WO1991001306A1 (fr) Derive oxoindole
EP2687531B1 (en) Tetrahydrocarboline derivative
CN101679363A (zh) 具有新型苯甲基（杂环甲基）胺结构的嘧啶化合物及含有其的药物
WO2011049127A1 (ja) 炭化水素環基を有する５－ヒドロキシピリミジン－４－カルボキサミド誘導体
JP2008503567A (ja) α−アリールメトキシアクリレート誘導体を含有する代謝性骨疾患の予防及び治療用医薬組成物
CN101098859A (zh) 嘧啶酮类化合物及其制备和用途
KR101091130B1 (ko) 로슈바스타틴의 전구체 및 그의 제조 방법
RU2639875C2 (ru) Производное фенила
JPH0231705B2 (zh)
CN102040517B (zh) 白藜芦醇衍生物及其医药用途
JPH0925235A (ja) １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤
WO2013147214A1 (ja) ５－ヒドロキシピリミジン－４－カルボキサミド誘導体
CN101974016A (zh) 酰胺类化合物及其制备方法和用途
KR101164426B1 (ko) 스타틴계열의 고지혈증 치료제 전구체와 그 중간체들 그리고 그들염의 제조방법
JP2009502748A (ja) 抗腫瘍に使用されるプシムベリン／イルシニアスタチンの合成及び完全な立体化学的分析
EP0433064A1 (en) Naphthylsulfonylalkanoic acid compounds
JP2567593B2 (ja) イミダゾリジントリオン誘導体及び該化合物を有効成分として含有するアレルギ−性疾患治療剤
JP2008521836A (ja) ロスバスタチンの調製

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1109393

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130306

Termination date: 20191223